<p class="email"><strong>Background</strong></p><p class="email">Microalbuminuria is the earliest evidence of diabetic nephropathy and a major predictor of end stage renal disease (ESRD). The objective of the study was to determine the influence of several risk factors on the presence of microalbuminuria in type 2 diabetics.</p><p><strong> </strong></p><p><strong>Methods</strong></p><p>This observational cross-sectional study was done on 73 patients with type 2 diabetes, who attended the <em>Prolanis</em> program in Primary Health Care from May to November 2018. Detailed medical histories including duration of diabetes and relevant clinical examinations including fasting blood sugar (FBS), post-prandial blood sugar (PPBS), HbA1c, serum creatinine, blood urea and urinary microalbumin were recorded for each patient. A multiple regression analysis was used to analyze the data. The analysis was assessed at 5% level of significance.</p><p><strong> </strong></p><p><strong>Results</strong></p><p>Mean age of study population was 51.89 ± 6.78 years with female preponderance (51.1%). Mean FBS, PPBS, HbA1c, duration of diabetes, systolic blood pressure, microalbuminuria and serum creatinine was 182.51 ± 74.63 mg/dL, 186.25 ± 26.72 mg/dL, 8.8 ± 1.83%, 9.37 ± 5.96 years, 118.44 ± 4.13 mmHg, 30.32 ± 3.2 mg/day and 1.33 ± 0.64 mg/dL respectively. Duration of diabetes and HbA1c were positively correlated with microalbuminuria (β=0.052; Beta =0.367; p<0.001 and β=0.058; Beta=0.363; p<0.001) respectively.</p><p><strong> </strong></p><p><strong>Conclusions</strong></p><p>Duration of diabetes was the most important risk factor of microalbuminuria in type 2 diabetes patients. Therefore microalbuminuria can predict diabetic nephropathy earlier, as a warning to prevent further worsening of diabetic complications.</p><p class="fax"> </p>
Objective: Liver cirrhosis and hepatocellular carcinoma (HCC) are chronic liver diseases that can cause serious health problems. Meanwhile, the methods used to detect liver cirrhosis and HCC are limited. Apolipoprotein A1 (ApoA1) is a protein that makes up high-density lipoprotein (HDL), which plays a role in liver cirrhosis and HCC, and can be used as a biomarker. This study aims to determine the ability of ApoA1 to detect and differentiate liver cirrhosis and hepatocellular carcinoma. Methods: This cross-sectional study was conducted on 47 patients with liver cirrhosis and HCC at Margono Soekarjo Regional General Hospital, Purwokerto, Indonesia. This study also involved 33 healthy participants from blood donors at the Blood Transfusion Unit, Indonesian Red Cross, Banyumas. Serum ApoA1 levels were analyzed by ELISA method. Receiver Operating Characteristics (ROC) were used to evaluate the diagnostic power of ApoA1 and differentiate between cirrhotic, HCC, and healthy patients. Multivariate binary logistic regression test to determine the most influential variables on the incidence of cirrhosis, HCC, and health. Results: ApoA1 was able to differentiate cirrhosis from HCC, cirrhosis from healthy and HCC from healthy, with sensitivity 56.7%, 86.7%, 70.6%, specificity 70.6%, 93.9%, 84.9%, respectively, and AUC 68.5%, 92.6%, 75.0%. AFP (p = 0.002, OR 1.004) and bilirubin (p = 0.021, OR 1.259) were variables that contributed to cirrhosis -HCC. Age (p = 0.011, OR 0.766) and AST (p = 0.003, OR 0.834) are variables that play a role in health -cirrhosis. ALT (p = 0.024, OR 0.965) and PT (p = 0.004, OR 0.253) are variables that play a role in healthy -HCC. Conclusion: ApoA1 was best for detecting healthy from cirrhosis, followed by healthy from HCC and cirrhosis from HCC. ApoA1 is not the primary variable determining the incidence of cirrhosis -HCC, healthy -HCC, and healthy -HCC.
Hypertension is often found in patients with type 2 diabetes. Albumin Creatinine Ratio (ACR) is used to detect early symptoms of kidney disease in patients with type 2 diabetes. The aim of this study is to determine the correlation between ACR and hypertension, as well as its relationship with other risk factors in type diabetes patients 2. Data were collected from 112 diabetic patients at PROLANIS FKTP Banyumas to see ACR and blood pressure. The results showed that poor glycemic control could be one of the risk factors. It can be concluded that detecting kidney dysfunction through ACR and starting treatment as early as possible can avoid the worst possibilities in type 2 diabetes patients.
Purwoceng (Pimpinella pruatjan Molk) is an original Indonesian herb which is known to have an aphrodisiac effect. The active compounds in Purwoceng potentially have hepatotoxic and nephrotoxic effects.This study was aimed to analyze the effect of subchronic administration of Purwoceng roots ethanol extract to Wistar Strain of Rattus norvegicus rats. The method of this subchronic toxicity study was an experimental post test only with control group design. Forty male Rattus norvegicus were randomly divided into four groups and get 28-days treatment. Group A as control received aquadest and 1% CMC (carboxymethyl cellulose), group B, C, and D were given Purwoceng roots ethanol extract of 42, 84, and 168 mg/KgBW/day and 1% CMC. Parameters tested were the levels of urea, creatinine, SGPT (serum glutamic pyruvic transaminase), SGOT(serum oxaloacetic pyruvic transaminase), kidney and hepar histopatology.The results showed a statistically significant for the liver histopathological in group B, creatinine, urea, and kidney histopathology in group C. Our study concluded that subchronic administration of Purwoceng (Pimpinella pruatjan Molk) roots ethanol extract could induce hepatotoxicity at the 42 mg/KgBW/day dose level and nephrotoxicity at the 84 mg/KgBW/day dose level.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.